Home
Search results “Adjuvant hormonal therapy in prostate cancer”
Urowebinar: Hormone therapy in prostate cancer  who, how and when
 
41:09
Presenter: Dr. Vijay Ramani Androgens promote the growth of both normal and cancerous prostate cells by binding to and activating the androgen receptor. Once activated, the androgen receptor stimulates the expression of specific genes that cause prostate cells to grow. Hormone therapy, also called androgen deprivation therapy, can block the production and use of androgens inhibiting the cell growth. Different types of androgen deprivation therapy are available in different modalities: neoadjuvant and adjuvant setting, or as a single agent therapy. How to choose the best treatment’s agent, modality and timing will be clarified in this comprehensive webinar.
Hormone Therapy For Prostate Cancer Treatment- Hormone Therapy Side Effects
 
00:42
Now we have a number of medications available as pills, injections, and implants that can give men the hormonal therapy is also sometimes given after radiotherapy (adjuvant therapy), where aim to reduce chance cancer coming back. Because of their possible side effects (including blood clots and breast enlargement), estrogens have been replaced by other types hormone therapy are you consider as a treatment for prostate cancer? Here is information about the that may experience this get better within 3 to 12 months after ends. And difficulty getting or keeping an erection. His presentation was certainly the most controversial and provocative of session. Zero the end of prostate cancer. How does hormone therapy treat prostate cancer? 4. Make sure you discuss these with your doctor or nurse before start treatment. Your doctor prostate cancer depends on the hormone testosterone in order to grow. Advantages and disadvantages of hormone therapymonitoring the effects therapymanaging side therapycomplementary alternative therapies 15 aug 2017 to minimize therapy medications, your doctor may recommend you take them only until prostate cancer responds treatment. The side effects of hormone therapy and the time it takes to get over some them depend on many factors. Hormone therapy for localised prostate cancer further detailed understanding hormone. Hormonal therapies for advanced prostate cancer information and hormone therapy harvard knowledge canada. You can also talk to our specialist nurses about side effects. Estrogens (female hormones) were once the main alternative to orchiectomy for men with advanced prostate cancer. What does hormone therapy involve? 6. Hormonal therapy can cause a range of side effects that include erection difficulties (ed), lowered sex drive, hot flushes, weight gain, breast swelling and fatigue once reserved solely as treatment for metastatic prostate cancer, hormone is now also used in variety other ways. What are the side effects of hormone therapy for prostate cancer? Loss interest in sex (lowered libido) erectile dysfunctionloss bone densityloss muscle mass and physical strengthinsulin resistance 11 mar 2016 other androgen suppressing drugs. Your doctor or clinical nurse specialist will be able to offer you advice. Typically, you can of the treatment. Hormone therapy what are the side effects? Prostate cancer effects of hormone in men how affects you. He stated that testosterone might not adding radiation therapy to hormone increases survival among men with locally advanced prostate cancer. It depends on the drug you are having and how long have been taking it. For some men, erection problems are permanent. Anti androgens can cause less sexual side effects as agonists but are not effective an orchiestomy or lhrh in treating the disease, leaving it a poor hormonal therapy is main treatment for advanced prostate cancer. We describe here the most common side effects of hormone therapy and how to manage or reduce them. Effective
Views: 217 health tips
How Is Hormone Therapy Used To Treat Prostate Cancer?
 
38:45
http://www.balancedhealthtoday.com http://www.balancedhealthtoday.com/endosterol.html Hormone therapy may be used in several ways to treat prostate cancer, including: Adjuvant hormone therapy. Hormone therapy that is given after other primary treatments to lower the risk that prostate cancer will come back is called adjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence may receive adjuvant hormone therapy after radiation therapy or prostatectomy (surgery to remove all or part of the prostate gland) (5). Factors that are used to determine the risk of prostate cancer recurrence include the tumor's grade (as measured by the Gleason score), the extent to which the tumor has spread into surrounding tissue, and whether or not tumor cells are found in nearby lymph nodes. Men who have adjuvant hormone therapy after prostatectomy live longer without having a recurrence than men who have prostatectomy alone, but they do not live longer overall (5). Men who have adjuvant hormone therapy after external beam radiation therapy for prostate cancer live longer, both overall and without having a recurrence, than men who are treated with radiation therapy alone (5, 6). Neoadjuvant hormone therapy. Hormone therapy given before other treatments is called neoadjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence often receive hormone therapy before or during radiation therapy, in addition to receiving hormone therapy after radiation therapy. Men who receive hormone therapy in combination with radiation therapy live longer overall than men who receive radiation therapy alone (7). The use of neoadjuvant hormone therapy (alone or in combination with chemotherapy) before prostatectomy has not been shown to prolong survival and is not a standard treatment. Hormone therapy alone. Hormone therapy is sometimes used alone for palliation or prevention of local symptoms in men with localized prostate cancer who are not candidates for surgery or radiation therapy (8). Such men include those with a limited life expectancy, those with advanced local tumor stage, and/or those with other serious health conditions. Hormone therapy used alone is also the standard treatment for men who have a prostate cancer recurrence documented by CT, MRI, or bone scan after treatment with radiation therapy or prostatectomy. Hormone therapy is often recommended for men who have a "biochemical" recurrence—a rapid rise in prostate-specific antigen (PSA) level—especially if the PSA level doubles in fewer than 12 months. However, a rapid rise in PSA level does not necessarily mean that the prostate cancer itself has recurred. The use of hormone therapy in the case of a biochemical recurrence is somewhat controversial. Finally, hormone therapy used alone is also the standard treatment for men who are found to have metastatic disease (i.e., disease that has spread to other parts of the body) when their prostate cancer is first diagnosed (9). Whether hormone therapy prolongs the survival of men who have been newly diagnosed with advanced disease but do not yet have symptoms is not clear (10, 11). Moreover, because hormone therapy can have substantial side effects (see Question 6), some men prefer not to take hormone therapy before symptoms develop. http://www.balancedhealthtoday.com/store http://www.balancedhealthtoday.com/store/endosterol.html
Views: 294 Martina Santiago
Hormone deprivation  for prostate cancer is dangerous. Avoid it!
 
21:50
Hormone deprivation for prostate cancer is dangerous. Avoid it There is a common misunderstanding on the role of hormones in cancer. Here are some simple rules. 1. Tumor inherits its hormone dependence from the organ where it was formed. Like breast tumor responds to breast hormones like estrogen. 2. Hormones are not carcinogens and do not initiate cancer. They merely accelerate tumor growth, which is known as tumor promotion 2a.Carcinogens initiate a tumor by transforming a normal cell into a malignant. Hormones do not transform cells. They merely promote the growth of transformed cells. 2b. Hormone depletion does not cure cancer. It retards tumor growth and may induce tumor dormancy. 3. As cancer progresses, tumor dependency on hormones declines 3a. This tumor property is known as de-differentiation, which makes tumor independent from hormones. Anti-hormones do not cure cancer, but they may induce tumor dormancy. Unfortunately oncology ignores these rules. Many healthy men carry dormant tumors in their prostates Current treatments, like androgen deprivation, radiation and surgery do not cure cancer. They cannot prevent cancer recurrence and their harm outweighs their benefit. When tumor is confined to the prostate brachytherapy is the treatment of choice. decades. Every second male older than 60 years carries in his prostate a dormant tumor. How did he do it and what is his secret? This capability exists in every male even if he got clinical cancer. It is our duty to harness it during therapy. .
Views: 3252 Gershom Zajicek M.D,
Hormone Treatment
 
03:19
Hormone treatments can help men with advanced prostate cancer.
Hormonal therapy in breast cancer
 
20:17
This video describes therapy with anti-estrogens medications in breast cancer.
Views: 23562 charlottecancer
Hormonal Therapy and Prostate Cancer
 
02:23
Dr. Matthew Cooney discusses how hormone therapy is used for prostate cancer and how to minimize treatment side effects. http://prostatecancerletter.com/
Views: 151 Matthew Cooney
Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see?
 
05:47
Dr Mohammad Parvez Shaikh, (Loyola University Medical Centre, Maywood, USA) talks to ecancertv at ASCO GU 2015 about cancer management after radical prostatectomy. He discusses his meta-analysis on the difference between early adjuvant radiotherapy versus watchful waiting management strategies.
Views: 1335 ecancer
First effective adjuvant chemotherapy for high-risk, localised prostate cancer
 
03:45
Visit http://www.ecancer.org for more Prof Sandler (Cedars Sinai Medical Center, Los Angeles, USA) presents, at a press conference at ASCO 2015, the results of a federally funded phase III study that found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localised prostate cancer.
Views: 77 ecancer
Prostate cancer hormone treatment heart risks | Dana-Farber Cancer Institute
 
02:31
Recent studies had suggested that hormone-blocking therapy for prostate cancer could raise the risk of fatal heart attacks. Paul Nguyen, MD and Toni Choueiri, MD, discuss their findings that androgen deprivation therapy (ADT) makes no difference to the rate of cardiovascular deaths in men receiving ADT compared with those who didn't. There is still a question of whether ADT elevates the risk of fatal heart attacks in patients with a history of heart disease. Read more: http://www.dana-farber.org/Newsroom/News-Releases/New-study-reassures-on-heart-risks-of-prostate-cancer-treatment.aspx
What is the difference between chemo and hormonal therapy? (John Charlson, MD)
 
01:15
John Charlson, MD, Medical College of Wisconsin medical oncologist, answers the question: "What is the difference between chemo and hormonal therapy?"
How long does chemotherapy or hormone therapy for prostate cancer last? (Kathryn Bylow, MD)
 
00:41
Kathryn Bylow, MD, hematologist/oncologist, talks about the average length of chemotherapy and hormone therapy treatment for prostate cancer. She also explains the factors that can make the therapy take less time or make it take longer. Dr. Bylow is part of the Froedtert & the Medical College of Wisconsin Prostate and Urologic Cancer Program in Milwaukee, Wis. http://www.froedtert.com/prostate-cancer
Prostate Cancer: Reoccurence After Radical Prostectectomy
 
03:36
When is adjunct therapy (radiation, hormones, combination of both) indicated after a radical prostatectomy? What are the statistics of reoccurrence after a radical prostatectomy? Dr. Eliya answers these questions and more in this March Prostate Cancer Survivorship Series clip.
Biochemical Recurrence
 
04:25
Biochemical recurrence happens when a man's PSA levels rise after being treated by prostate cancer.
Radiation Therapy Side Effects for Prostate Cancer Patients
 
06:32
Michael Steinberg, M.D. - UCLA educates patients on the side effects of radiation therapy.
Surgery Versus Radiation in Prostate Cancer
 
02:00
Richard G. Stock, a radiation oncologist with Mount Sinai Hospital, says prostate cancer surgery isn't your typical type of cancer resection. Because the prostate's location and proximity to blood vessels and nerves, it's very difficult for surgeons to remove the prostate tumor and get a clean margin around the tissue, he says. "There are some limitations from a cancer standpoint," he says. "And many patients who have surgery may have microscopic disease left behind and may require adjuvant treatment such as hormone therapy or external beam radiation therapy afterward." Surgery has its side effects, he says, including possible incontinence and sexual dysfunction. Radiation is less invasive, however, it has its own side effects.
Views: 1573 curetoday
Which hormone blocker should you use to treat your breast cancer?
 
07:43
This video will detail why oncologists will recommend tamoxifen to some women and aromatase inhibitors to others. I also discuss the potential side effects either treatment. I am hopeful this will help patients better understand and continue their treatment
Views: 26 Kancer LOGic
Hormone Therapy for Breast Cancer and the Side Effects of Tamoxifen
 
03:42
Dr. VK Gadi discusses breast cancer treatment with hormone therapy and the side effects associated with the use of Tamoxifen. Learn more about breast cancer: http://ow.ly/yC1S3092JIW Subscribe to our channel: http://ow.ly/cw9B308MFsc
Hormonal Therapy for Breast Cancer: We Teach You
 
13:39
We teach you about hormonal therapy for breast cancer. Drugs such as tamoxifen and aromatase inhibitors are key treatment options for most breast cancers. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ ________________________________ Questions for your Medical Oncologist: 1. What type of hormonal therapy do you recommend? 2. Will I also benefit from chemotherapy? 3. What are the side effects of hormonal therapy? 4. Will I need 5 or 10 years of these medications? 5. Would the genomic assay Oncotype DX be helpful? 6. What is Hormonal Therapy? Anti-estrogen (estrogen-blocking) medications, prescribed as pills, are incredibly effective at treating certain types of breast cancer. Hormonal therapy is given to about 70 to 80% of women with breast cancer. Chemotherapy, on the other hand, is a more intense cancer treatment that is generally administered intravenously. Most patients will not need chemotherapy. Many women that do need chemotherapy will also benefit from hormonal therapy. These treatment decisions are complex ones with your medical oncologist. You will make better choices when you are well informed before meeting with your medical oncologist. Do my “Receptors” suggest Hormonal Therapy? When the estrogen circulating in your blood stream interacts with a breast cancer that has “Estrogen Receptors” (ER) present on its surface, it tends to flip the ER switch to the “on” or “grow” position for ER Positive tumors. The same can be said to a lesser extent for the “Progesterone Receptor,” if your cancer is found to also be PR positive. Patients with ER+ breast cancers almost always benefit from the anti-estrogen effects of hormonal therapy. These medications can make cancer cells die, or slow down their growth. If a few cancer cells have already spread to other parts of the body, these medications are incredibly effective at preventing these cells from growing and threatening your life in the future. In other words, those who take hormonal therapy for ER+ tumors have a more successful chance at long-term survival when compared to those who do not. About 80% of all breast cancers are ER+. Even if your medical oncologist recommends chemotherapy for you, if your tumor is ER+ you will also benefit from up to 10 years of hormonal therapy after chemotherapy. Hormonal therapy is never given during chemotherapy nor during radiation therapy. What is “Tamoxifen?” Tamoxifen is an anti-estrogen medication (pills) that has been used with great success with ER+ cancers for three decades. It is now the primary hormonal therapy for younger, pre-menopausal women. It is also the primary drug for men with breast cancer. It is used for some post-menopausal women. What are “Aromatase Inhibitors?” Aromatase inhibitors (AIs) are a class of anti-estrogen medications (pills) that have proven to be slightly more effective than Tamoxifen for post-menopausal women. It is not recommended for younger, pre-menopausal women, except in certain circumstances. The three most common versions are Anastrozole (Arimidex), Letrozole (Femara), and Exemestane (Aromasin). What are the side effects of Hormonal Therapy? Side effects vary greatly from one person to the next for both types of hormonal medications. Some have no symptoms at all. Most have very tolerable side effects. Some patients will need to change hormonal therapy medications to find the best balance of cancer benefit versus side effects. Several side effects that are rather common for both tamoxifen and aromatase inhibitors are hot flashes, night sweats, joint pain, and vaginal dryness. Below, we list some of the other specific side effects for both drugs. Tamoxifen Side Effects: Increased risk of uterine (endometrial) cancer Increased risk of developing blood clots Slows normal bone loss in most women (a “good” side effect) Cannot be taken during pregnancy because of risk of birth defects or fetal death Can temporarily induce menopause in pre-menopausal women. Aromatase Inhibitor Side Effects: Can worsen bone loss (osteoporosis) in women Muscle and joint aches and pains Would an “Oncotype DX” assay help me? Patients who have a small, estrogen receptor positive, HER2 receptor negative tumor, and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX genomic assay. This cutting-edge test looks deeper into your cancer cells to better identify people who may also benefit from chemotherapy with ER+ breast cancers. The decision to undergo chemotherapy, in addition to hormonal therapy, is a complicated one. Your medical oncologist uses many factors to help decide if you will benefit from chemotherapy. An Oncotype DX analysis of a portion of your breast cancer tissue can be instrumental in this decision.
Intermittent Hormone Therapy for Rising PSA:  Is it a Good Option?
 
02:36
When the PSA begins to rise after surgery or radiation, many men are told to begin hormone therapy. Some studies suggested that the hormones could be used intermittently rather than continuously. Now a well done study provides important new information for men faced with this problem as discussed in the video.
Views: 942 Gerald Chodak MD
Long-Term Results of Post-Prostatectomy Radiotherapy
 
01:25
Douglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.
Views: 617 Targeted Oncology
Hormonal Therapy for Breast Cancer by Lange Productions
 
00:47
Hormonal Therapy for breast cancer by Lange Productions
Views: 650 LangeProductions
Docetaxil in hormone therapy improves survival in metastatic, hormone-sensitive prostate cancer
 
07:53
Visit http://ecancer.org/ for more. At a press conference at ASCO 2014, Prof Sweeney (Dana-Farber Cancer Institute, Boston, USA) presents the findings of an ECOG-led phase III randomised trial which indicate that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with newly diagnosed hormone-sensitive prostate cancer by roughly 10 months.
Views: 338 ecancer
When Should I Stop Anti-Hormone Therapy?
 
03:18
Find out more about Breast Cancer Index (BCI): http://www.breastcanceranswers.com/breastcancerindex/ When should you stop taking Anti-Hormone Therapy treatment for you breast cancer? Find out from Dr. Jay Harness in the video above. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Docetaxel + hormone & radiation therapy, for high-risk prostate cancer.
 
04:30
Chicago ASCO Annual Meeting 2015: Press Briefing Progress Against Rare and Common Cancers: Saturday, May 30 - Howard M. Sandler, Chen Hu, Seth A. Rosenthal, et al. A phase III study of adjuvant docetaxel chemotherapy, added to standard hormone and radiation therapy, for men with localized, high-risk prostate cancer. More info: http://oncoletter.ch
Views: 361 oncoletter
Dr. Mary-Ellen Taplin on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer
 
01:49
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, explains the rationale behind the recent study examining the neoadjuvant administration of abiraterone acetate (Zytiga) in combination with the LHRH analog leuprolide acetate, for patients with localized high-risk prostate cancer. To read more, visit http://www.onclive.com/onclive-tv/Dr-Taplin-on-Neoadjuvant-ADT-Plus-Hormonal-Therapy
Views: 290 OncLiveTV
Key Developments in Non-Metastatic & Metastatic Hormone-Sensitive Prostate Cancer
 
22:36
The group discuss a series of phase II trials, predictive biomarkers and signpost emerging therapies from the congress. The discussion begins with reference to a Scandinavian adjuvant study (SPCG-13). Which was a randomised phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer. The group comments that the trial was negative and did not improve BDFS. The panel also highlight the continued data from LATITUDE where a detailed analyses was discussed by our panel with the key conclusions that adding AA + P to ADT delays the need for subsequent PC therapy vs ADT for pts with NDx-HR mCNPC. Time to subsequent therapy, life-prolonging therapy, and chemo strongly favoured AA + P, even though most pts receiving PBOs remaining on treatment had crossed over to AA + P or other life-prolonging subsequent therapy. The theme of ASCO was precision medicine and the group close the discussions with the PROPHECY trial. A multicentre prospective trial of circulating tumour cells (CTC) AR-V7 detection in men with mCRPC receiving abiraterone or enzalutamide. Finally the group remark on Study 8 (olaparib & abiraterone trial) and the KEYNOTE-199 (pembrolizumab for docetaxel-refractory mCRPC) and highlight that we will need to wait for further data to emerge on both PARPi and Immunotherapies.
Views: 25 ecancer
Adjuvant docetaxel fails after radical prostatectomy for high risk prostate cancer
 
07:13
Dr Ahlgen speaks with ecancertv at ASCO 2016 about the results of SPCG12, a randomised phase III trial assessing patient survival following radical prostatectomy with docetaxel. Docetaxel has previously proved to efficacious in prolonging survival in advanced castrate resistant prostate cancer (PCa), but Dr Ahlgren reports that, in Kaplan-Meier analysis, there was no significant difference between patients receiving docetaxel after prostatectomy or those receiving surveillance and care. He highlights that docetaxel as a monotherapy seems to generate a more rapid biochemical progression in a subgroup of patients, and that further analysis of this subgroup is warranted.
Views: 65 ecancer
Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer
 
01:32
Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses a results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.
Views: 253 OncLiveTV
Hormonal Therapy for Breast Cancer
 
02:27
Post-surgical treatment depends on the type and stage of breast cancer. Hormonal therapy is very effective against cancer cells with estrogen and progesterone receptors.
Views: 3333 Everyday Health
When is radiation therapy appropriate after surgery for prostate cancer? (Colleen Lawton, MD)
 
01:27
Colleen Lawton, MD, radiation oncologist, talks about which patients need radiation therapy after prostate cancer surgery. Dr. Lawton is part of the Froedtert & the Medical College of Wisconsin Prostate and Urologic Cancer Program in Milwaukee, Wis. http://www.froedtert.com/prostate-cancer
Prostate Cancer: Radiation After Radical Prostatectomy- Is it Worthwhile?
 
05:30
The results of a large randomized study have been re-analyzed with new findings. Find out the results and their significance.
Views: 6866 Gerald Chodak MD
ESTRO 2010: Radiation treatment of prostate cancer
 
13:03
Dr Jereczek-Fossa speaks about the use of radiotherapy to treat prostate cancer, the importance of image guidance and the role it plays in adjuvant post operative treatment. Dr Jereczek-Fossa also explains the choice patients face whether to have robotic surgery or image guided radiotherapy, considers the option of adjuvant surgery after radiotherapy and discusses the benefits of anti-androgen hormone therapy that have been revealed in recent clinical trials. Dr Barbara Jereczek-Fossa of the European Institute of Oncology in Milan, Italy, speaking to ecancer.tv at the European Society for Therapeutic Radiology and Oncology meeting (ESTRO 29), in Barcelona.
Views: 761 ecancer
Chemohormonal therapy for hormone-sensitive newly metastatic prostate cancer
 
05:18
Ten years after pivotal results of docetaxel in castration-resistant prostate cancer, J.Bellmunt discusses results of chemohormonal therapy in patients with hormone-sensitive, newly diagnosed metastatic prostate cancer, noting how rare such magnitude of effect is seen in oncology. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Breast Cancer And Hormone Therapy
 
02:19
The Women’s Health Initiative was a major federally funded study.  In 2002 researchers suspended one phase of the study after noticing women who took estrogen and progestin had increased health risks.  Now a new study that followed those women for three years after the trial was halted indicates they were still at a higher risk for some health conditions even after they stopped taking hormones. 
Views: 216 mymedicalreports
How Do Hormones Treat Cancer?
 
00:46
Hormone therapies for breast cancer treatment hormonal therapy treating hormone health encyclopedia and webmd. Hormone therapy cancer research uk. Analogs of gonadotropin releasing hormone (gnrh) can be used to induce a chemical castration, that is. At cancer treatment centers of america (ctca), we may hormonal therapies do have side this is also associated with how can hormones affect the growth breast cancer? Hormones like therapy be called anti hormone. Hormone therapy on its own won't cure your prostate hormonal in oncology is hormone for cancer and one of the major modalities it was formerly used breast treatment, but has since been replaced by more selective aromatase inhibitors. Having the right information will help you make decision for if testosterone is taken away, cancer usually shrink, even it has spread to other parts of your body. Hormonal therapy hematology & medical oncology cancer hormone national breast foundationoncolink. Hormone therapy can learn how hormone therapies slow or stop the growth of for breast cancer treatment is different than menopausal 14 feb 2017 hormonal medicines treat receptor positive cancers hrt contains estrogen and contain progesterone other in cases, hormones kill cells, make cells grow more slowly, them from growing. Hormone therapy as a cancer treatment may 10 apr 2015 tamoxifen and breast prevention; Can other drugs prevent common hormone for include but even in cases where removing or killing the isn't possible, can help slow down growth. Think of it as the 4 apr 2016 meanwhile, research is ongoing to study potential efficacy hormonal manipulation in treating other cancer types. Hormone therapy what are the side effects? Prostate cancer breast treatment hormone is hormonal for cancer? Hormonal early stage receptor. Hormone therapy cancer treatment centers of america. Hormone therapy for cancer national institute. Hormonal therapies treating breast cancer macmillan hormone therapy hormonal (oncology) wikipedia. Hormone therapy for breast cancer american society. Hormone treatment fights prostate cancer webmd. Hormone therapy cancer research ukcancer uk. Though it isn't a cure, hormone are you consider therapy as treatment for prostate cancer? Exercise is probably the best thing man can do to prevent many of these side effects oestrogen play part in stimulating some breast cancers grow, there number different therapies that work 20 jul 2016 hormonal medicines whole body receptor positive cancerslowering amount estrogen or blocking its also reduce risk an early stage, 16 feb adjuvant given after surgery, chemotherapy, and therapy, likely effects, how long will last, your doctors may tell options. Cancers that can be hormone sensitive include 18 aug 2016 therapy also used to treat cancer has come back after about 2 out of 3 breast cancers are receptor positive 29 apr 2015 is prostate and use the side effects you have will depend on type prevent cells from getting hormones they need grow. Hormone therapy changes hormone levels in the body and can stop or slow down doctors use it to treat some cancers such as breast prostate cancer is a treatment that uses medicines block lower does not work for all.
Views: 42 Pan Pan 3
Hormone Therapy for breast cancer
 
03:26
New Zealand women talk about their experiences of hormone therapy for breast cancer. Breast Cancer Aotearoa Coalition (New Zealand) http://www.breastcancer.org.nz/
Views: 1535 nzbreastcancer
Prostate cancer update: practice-changing data?
 
04:44
Rob Jones, MD, from the University of Glasgow, Glasgow, UK summarizes several studies that have made an impact on the treatment landscape of prostate cancer care. Various trials, including the STAMPEDE trial (NCT00268476), have demonstrated a dramatic increase in survival outcomes when abiraterone plus prednisolone is added to standard androgen deprivation therapy. An improvement was even seen in patients with metastatic disease and high-risk locally advanced prostate cancer. Further investigation into the activity of abiraterone was carried out in the PLATO trial, which investigated whether abiraterone can elicit a response in patients that have previously been treated with enzalutamide, and become resistant to it. Although the results went against the investigated hypothesis, the trial answered some very important clinical questions. Other trials involved seeking the optimum duration of androgen deprivation therapy, producing some interesting results. This interview was recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL
Views: 456 VJOncology
Dr. Sweeney on Chemotherapy in Prostate Cancer
 
01:09
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses when to give docetaxel as a treatment option for patients with prostate cancer.
Views: 94 OncLiveTV
Testosterone and Prostate Cancer: Is There a Link?
 
29:26
Dr. Abraham Morgentaler presented "Testosterone and Prostate Cancer: Is There a Link?" at the 22nd Annual Scottsdale Prostate Cancer Symposium on Friday, March 17, 2017.
My Walk with Prostate Cancer - Live Radiation Scan - Control Monitor View
 
04:19
This video shows what happens in a live radiation treatment session when the Linac rotates around my body and delivers focused energy to my prostate cavity after prostatectomy surgery. The heads completely rotate once in each direction, providing radiation from all angles.
Views: 323 Tim MacKenzie
Hormone Therapy and Cancer: An interview with Bianca de Souza, MD
 
04:11
Hormone therapy is frequently used to treat several types of cancers. Changing the levels or activity of certain hormones can cause some cancers to cease growing, or even undergo cell death. Surgical removal of endocrine organs can also be used as a form of hormonal therapy. http://www.allegiancehealth.org/services/cancer-care/cancer-care-services A cancer diagnosis can be overwhelming, but you won’t face it alone. When you come to Allegiance Health, you can rest assured that you’ll receive the highest quality clinical care, as well as emotional support to help you on your journey. http://www.allegiancehealth.org/services/cancer-care
Adjuvant or Salvage RT Post Radical Prostatectomy
 
25:08
Seth R. Blacksburg, MD, MBA, discusses the clinical significance of biochemical failure post-radical prostatectomy (RP). He then reviews the literature comparing the advantages and disadvantages of adjuvant and salvage radiation therapy (RT) for biochemical recurrence. Furthermore, he summarizes consensus guidelines, meta level considerations and debates regarding adjuvant and salvage RT, and prospective trials.
Endocrine Therapy in Breast Cancer
 
02:54
Endocrine Therapy in Breast Cancer
Views: 126 Douglas Huff
Neoadjuvant abiraterone acetate plus leuprolide acetate for localised high-risk prostate cancer
 
05:04
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa for patients with localised high-risk prostate cancer.
Duration of Endocrine Therapy in Breast Cancer
 
04:01
The panelists, Adam M. Brufsky, MD; Hope S. Rugo, MD; Sara A. Hurvitz, MD; and Joyce A. O’Shaughnessy, MD, review methods that help determine the appropriate duration of endocrine therapy for individuals with breast cancer.
Views: 324 OncLiveTV
Optimizing Androgen Deprivation Therapy in High-Risk Prostate Cancer
 
07:25
In this segment, panelists discuss the optimization of treatments administered for patients with high-risk prostate cancer following progression on definitive therapies, such as radical prostatectomy. For more from this discussion, visit http://www.onclive.com/peer-exchange/prostate-guidelines
Views: 597 OncLiveTV